The estimated Net Worth of Patrick J Heron is at least $6.82 million dollars as of 6 September 2024. Mr. Heron owns over 230 units of Mirum Pharmaceuticals Inc stock worth over $6,797,509 and over the last 10 years he sold MIRM stock worth over $0. In addition, he makes $19,308 as Independent Director at Mirum Pharmaceuticals Inc.
Patrick has made over 13 trades of the Mirum Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 230 units of MIRM stock worth $9,563 on 6 September 2024.
The largest trade he's ever made was buying 550,000 units of Mirum Pharmaceuticals Inc stock on 3 March 2020 worth over $9,900,000. On average, Patrick trades about 73,745 units every 111 days since 2015. As of 6 September 2024 he still owns at least 162,193 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Mr. Heron stock trades at the bottom of the page.
Patrick J. Heron serves as Independent Director of the Company. Mr. Heron is a general partner with Frazier, a position he has held since September 1999. Mr. Heron has been active in company formations and initial investments in various biotechnology companies, including Marcadia Biotech Inc., Calixa Therapeutics, Inc. and VentiRx Pharmaceuticals, Inc. He also led Frazier’s involvement in MedPointe Inc. Prior to joining Frazier, Mr. Heron helped develop McKinsey & Co.’s west coast biotechnology consulting practice. Mr. Heron currently serves on the board of directors of Iterum Therapeutics pic, a public pharmaceutical company, as well as private companies Amunix Therapeutics, Inc., Imago Biosciences, Inc., Arcutix, Inc., SutroVax, Inc., ScoutBio, Inc., and PassageBio, Inc. He previously served on the boards of directors of the public biopharmaceutical companies Tobira and Collegium Pharmaceuticals, Inc. Mr. Heron received a B.A. in Political Science from the University of North Carolina at Chapel Hill and an MBA from Harvard Business School.
As the Independent Director of Mirum Pharmaceuticals Inc, the total compensation of Patrick Heron at Mirum Pharmaceuticals Inc is $19,308. There are 11 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.
Patrick Heron is 49, he's been the Independent Director of Mirum Pharmaceuticals Inc since 2018. There are 11 older and 7 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.
Patrick's mailing address filed with the SEC is , 1001 PAGE MILL RD, BUILDING 4, SUITE B, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: